Alzheimer''s and Dementia: Diagnosis, Assessment and Disease Monitoring最新文献_第6页

Introduction to the special issue on ethics and equity in implementing novel biomarkers for Alzheimer's disease and related dementias: current progress and new directions. 介绍在阿尔茨海默病和相关痴呆实施新的生物标志物的伦理和公平：目前的进展和新的方向特刊。

IF 4.4

Alzheimer''s and Dementia: Diagnosis, Assessment and Disease Monitoring Pub Date : 2026-08-24 eCollection Date: 2026-07-01 DOI: 10.1002/dad2.70352

Fred B Ketchum, Annalise Rahman-Filipiak

引用次数: 0

Anti-amyloid immunotherapy and brain volume trajectories in early-onset versus late-onset Alzheimer's disease. 早发性与晚发性阿尔茨海默病的抗淀粉样蛋白免疫治疗和脑容量轨迹

IF 4.4

Alzheimer''s and Dementia: Diagnosis, Assessment and Disease Monitoring Pub Date : 2026-08-22 eCollection Date: 2026-07-01 DOI: 10.1002/dad2.70457

Rashi I Mehta, Methasit Jaisa-Aad, Camila Vieira Ligo Teixeira, Patrick D Worhunsky, Joseph E Malone, Melanie Ward, Cierra M Keith, Holly E Phelps, Khalid Sharif, Stephanie Pockl, Nafiisah Rajabalee, Gary D Marano, Lauren Bojarski, Samantha Smith, Kayla M Massey, Marcus Hatfield, Pierre-François D'Haese, Ali R Rezai, Marc W Haut

{"title":"Anti-amyloid immunotherapy and brain volume trajectories in early-onset versus late-onset Alzheimer's disease.","authors":"Rashi I Mehta, Methasit Jaisa-Aad, Camila Vieira Ligo Teixeira, Patrick D Worhunsky, Joseph E Malone, Melanie Ward, Cierra M Keith, Holly E Phelps, Khalid Sharif, Stephanie Pockl, Nafiisah Rajabalee, Gary D Marano, Lauren Bojarski, Samantha Smith, Kayla M Massey, Marcus Hatfield, Pierre-François D'Haese, Ali R Rezai, Marc W Haut","doi":"10.1002/dad2.70457","DOIUrl":"10.1002/dad2.70457","url":null,"abstract":"Introduction: Accelerated brain volume loss has been observed following trials of anti-amyloid beta immunotherapy (AAT); however, there is limited understanding of this paradoxical phenomenon in early-onset Alzheimer's disease (EOAD) versus late-onset Alzheimer's disease (LOAD).Methods: We retrospectively analyzed brain volume changes over a 1-year period following initiation of AAT. Annualized rates of brain volume alteration were calculated, and linear mixed-effects models were performed to assess brain volume trajectories in EOAD versus LOAD.Results: One hundred fourteen participants (35 with EOAD; 79 with LOAD; mean baseline MMSE: 27) were analyzed. Ventricular expansion, measuring ∼15%/year, and whole-brain atrophy occurred in both groups. LOAD showed ∼1.7× greater hippocampal atrophy compared with EOAD, independent of baseline cerebral amyloid burden, though global cortical amyloid burden predicted whole-brain and hippocampal atrophy (p < 0.001).Discussion: Brain atrophy with prominent ventricular expansion occurs in early-stage EOAD and LOAD following AAT. Additional studies are needed to elucidate the mechanisms and implications of this post-immunotherapy effect.","PeriodicalId":53226,"journal":{"name":"Alzheimer''s and Dementia: Diagnosis, Assessment and Disease Monitoring","volume":"18 3","pages":"e70457"},"PeriodicalIF":4.4,"publicationDate":"2026-08-22","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC13499008/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"148801495","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

IF 4.4

Alzheimer''s and Dementia: Diagnosis, Assessment and Disease Monitoring Pub Date : 2026-08-19 eCollection Date: 2026-07-01 DOI: 10.1002/dad2.70459

Yuki Oi, Qian Shen, Seraphina K Solders, Charlotte S Rivera, McKenna E Williams, Emilie T Reas

{"title":"APOE ε4-related blood-brain barrier disruption and APOE ε4-independent microstructural abnormalities in white matter hyperintensities.","authors":"Yuki Oi, Qian Shen, Seraphina K Solders, Charlotte S Rivera, McKenna E Williams, Emilie T Reas","doi":"10.1002/dad2.70459","DOIUrl":"https://doi.org/10.1002/dad2.70459","url":null,"abstract":"Introduction: While the apolipoprotein E (APOE) ε4 allele promotes blood-brain barrier (BBB) permeability and microstructural disruption, its specific contribution to white matter hyperintensity (WMH) pathological heterogeneity remains unknown.Methods: We measured BBB permeability (K trans) in 31 and microstructure in 59 cognitively normal older adults with WMHs and normal-appearing white matter (NAWM) using dynamic contrast-enhanced magnetic resonance imaging and restriction spectrum imaging (RSI). Linear mixed-effects models (LMMs) examined differences between WMHs and NAWM by APOE ε4 status.Results: In APOE ε4 carriers, K trans was elevated and restricted isotropic diffusion (RI) was reduced within WMHs compared to NAWM. This effect was absent in non-carriers. In contrast, reduced restricted directional diffusion and elevated isotropic free water within WMHs was observed in both genotypes. K trans did not correlate with brain microstructure.Discussion: Our data suggest that WMHs comprise both APOE ε4-related and APOE ε4-independent pathological components. These findings implicate neurovascular and non-vascular mechanisms through which APOE ε4 may contribute to WMH pathological heterogeneity.","PeriodicalId":53226,"journal":{"name":"Alzheimer''s and Dementia: Diagnosis, Assessment and Disease Monitoring","volume":"18 3","pages":"e70459"},"PeriodicalIF":4.4,"publicationDate":"2026-08-19","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC13490850/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"148801513","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

Cerebrospinal fluid biomarkers for cerebral amyloid angiopathy with non-hemorrhagic imaging marker. 脑淀粉样血管病的脑脊液生物标志物与非出血性成像标志物。

IF 4.4

Alzheimer''s and Dementia: Diagnosis, Assessment and Disease Monitoring Pub Date : 2026-08-19 eCollection Date: 2026-07-01 DOI: 10.1002/dad2.70431

Alexander Sekita, Maximilian I Sprügel, Stefanie Balk, David Haupenthal, Tobias Engelhorn, Manuel Alexander Schmidt, Arnd Doerfler, Timo Jan Oberstein, Juan Manuel Maler, Johannes Kornhuber, Piotr Lewczuk, Veit Rothhammer, Stefan Schwab, Joji B Kuramatsu, Jochen A Sembill

{"title":"Cerebrospinal fluid biomarkers for cerebral amyloid angiopathy with non-hemorrhagic imaging marker.","authors":"Alexander Sekita, Maximilian I Sprügel, Stefanie Balk, David Haupenthal, Tobias Engelhorn, Manuel Alexander Schmidt, Arnd Doerfler, Timo Jan Oberstein, Juan Manuel Maler, Johannes Kornhuber, Piotr Lewczuk, Veit Rothhammer, Stefan Schwab, Joji B Kuramatsu, Jochen A Sembill","doi":"10.1002/dad2.70431","DOIUrl":"10.1002/dad2.70431","url":null,"abstract":"Introduction: Reduced cerebrospinal fluid (CSF) amyloid beta (Aβ) 40 has been reported in cerebral amyloid angiopathy (CAA) diagnosed by hemorrhagic magnetic resonance imaging (MRI) markers. Whether similar alterations occur when fulfilling Boston Criteria 2.0 solely through non-hemorrhagic markers remains unclear.Methods: We analyzed 358 memory clinic patients undergoing MRI and CSF assessment. CAA was categorized by hemorrhagic markers (CAA 1.5 H) or exclusively non-hemorrhagic markers (CAA 2.0 NH) per Boston Criteria 1.5 and 2.0, respectively. Primary comparison of CSF-Aβ40 between CAA groups was complemented by secondary (Aβ42, phosphorylated tau [p-tau181], total tau [t-tau]) and exploratory analyses including Alzheimer's disease (AD), mild cognitive impairment (MCI), and healthy controls, adjusted for age, sex, MRI characteristics, and assay type.Results: Sixty-five patients were reclassified as CAA 2.0 NH. Aβ40 was higher in CAA 2.0 NH than CAA 1.5 H (15,808 vs. 13,792 pg/ml, p = 0.033) and did not differ from AD, MCI, or controls. p-tau181 reached significance after adjustment (p = 0.010), likely reflecting AD co-pathology. However, within CAA-2.0-NH, patients with AD CSF profile showed Aβ40 comparable to hemorrhagic CAA.Discussion: Non-hemorrhagic imaging markers alone were not associated with characteristic CAA-related CSF alterations, suggesting biological heterogeneity, limited specificity, or lesion type-dependent variability.","PeriodicalId":53226,"journal":{"name":"Alzheimer''s and Dementia: Diagnosis, Assessment and Disease Monitoring","volume":"18 3","pages":"e70431"},"PeriodicalIF":4.4,"publicationDate":"2026-08-19","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC13490837/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"148801520","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

Real-world determinants of time to initiation of anti-amyloid treatments: comparative data from private and academic practice settings. 抗淀粉样蛋白治疗开始时间的现实世界决定因素：来自私人和学术实践设置的比较数据。

IF 4.4

Alzheimer''s and Dementia: Diagnosis, Assessment and Disease Monitoring Pub Date : 2026-08-19 eCollection Date: 2026-07-01 DOI: 10.1002/dad2.70436

Varun Mehta, Divya Singh, Jordyn Kelman, Saanvi Nimma, Helen Lutz, Andrea Schnee, David Weisman, Michael H Rosenbloom

{"title":"Real-world determinants of time to initiation of anti-amyloid treatments: comparative data from private and academic practice settings.","authors":"Varun Mehta, Divya Singh, Jordyn Kelman, Saanvi Nimma, Helen Lutz, Andrea Schnee, David Weisman, Michael H Rosenbloom","doi":"10.1002/dad2.70436","DOIUrl":"https://doi.org/10.1002/dad2.70436","url":null,"abstract":"Introduction: Earlier anti-amyloid therapy (AAT) initiation results in improved clinical outcomes in Alzheimer's disease (AD). We sought to identify demographic, clinical, and disease-related factors impacting door-to-treatment times (DTTs).Methods: A retrospective review of AAT data was conducted at private and academic neurological practices.Results: A total of 329 patients (53.2% from private versus 46.8% academic practices), mean age 73.5 ± 7.2 (55.3% female), with most being non-Hispanic White were treated with lecanemab (81.2%) or donanemab (18.2%). DTTs were significantly reduced (p < 0.05) in both practices when diagnosis was confirmed with blood-based biomarkers (BBBs) as well as with greater clinic experience dosing AATs. DTT increased in patients with non-Medicare insurance and was not impacted by diagnosis, referral source, apolipoprotein E genotype status, or clinic distance.Discussion: Patients with private insurance may experience greater delay in DTT, whereas BBBs may reduce DTT relative to traditional confirmatory biomarkers. DTT improves with clinic experience.","PeriodicalId":53226,"journal":{"name":"Alzheimer''s and Dementia: Diagnosis, Assessment and Disease Monitoring","volume":"18 3","pages":"e70436"},"PeriodicalIF":4.4,"publicationDate":"2026-08-19","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC13490854/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"148801436","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

Adaptive testing for smartphone-based cognitive screening: Reducing patient burden while maintaining classification accuracy. 基于智能手机的认知筛查的自适应测试：在保持分类准确性的同时减少患者负担。

IF 4.4

Alzheimer''s and Dementia: Diagnosis, Assessment and Disease Monitoring Pub Date : 2026-08-19 eCollection Date: 2026-07-01 DOI: 10.1002/dad2.70455

Stephanie Ruth Young, Julia Yoshino Benavente, Elizabeth McManus Dworak, Michael S Wolf, Cindy J Nowinski

{"title":"Adaptive testing for smartphone-based cognitive screening: Reducing patient burden while maintaining classification accuracy.","authors":"Stephanie Ruth Young, Julia Yoshino Benavente, Elizabeth McManus Dworak, Michael S Wolf, Cindy J Nowinski","doi":"10.1002/dad2.70455","DOIUrl":"https://doi.org/10.1002/dad2.70455","url":null,"abstract":"Introduction: Remote cognitive screening for primary care must balance accuracy with patient burden. We evaluated whether adaptive task administration could reduce testing while preserving classification accuracy.Methods: Using data from older adults (N = 277; 100 mild cognitive impairment [MCI]; 177 normal cognitive aging) who self-administered MyCog Mobile, we developed a stepped protocol in which the final task is skipped when preceding tasks classify the patient with confidence. Leave-one-out cross-validation (LOO-CV) assessed agreement with the full-battery classification and accuracy relative to the reference diagnosis.Results: Thirty-three percent of participants were classified at the initial decision point, and only 17% required the full battery. LOO-CV showed a negligible change in area under the curve (ΔAUC = 0.008; bootstrapped 95% confidence interval [-0.004, 0.021]) using the adaptive battery.Discussion: Approximately one third of older adults can be accurately classified as with MCI using only two MyCog Mobile tasks under an adaptive approach. Prospective validation, in which the adaptive battery is administered in real time, is warranted.","PeriodicalId":53226,"journal":{"name":"Alzheimer''s and Dementia: Diagnosis, Assessment and Disease Monitoring","volume":"18 3","pages":"e70455"},"PeriodicalIF":4.4,"publicationDate":"2026-08-19","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC13490832/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"148801489","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

Experience with donanemab over a 1-year period: observations of side effects and compliance from a regional specialty medical center. donanemab在1年期间的使用经验：来自区域专业医疗中心的副作用和依从性观察。

IF 4.4

Alzheimer''s and Dementia: Diagnosis, Assessment and Disease Monitoring Pub Date : 2026-08-18 eCollection Date: 2026-07-01 DOI: 10.1002/dad2.70438

Lisa B E Shields, Hannah S Hust, Gregory E Cooper, Theresa Kluthe, Rachel N Hart, Andrew P Thaliath, Brandon C Dennis, Stephanie W Freeman, Jessica F Cain, Whoy Y Shang, Kendall M Wasz, Adam T Orr, Christopher B Shields, Shirish S Barve, Kenneth G Pugh

{"title":"Experience with donanemab over a 1-year period: observations of side effects and compliance from a regional specialty medical center.","authors":"Lisa B E Shields, Hannah S Hust, Gregory E Cooper, Theresa Kluthe, Rachel N Hart, Andrew P Thaliath, Brandon C Dennis, Stephanie W Freeman, Jessica F Cain, Whoy Y Shang, Kendall M Wasz, Adam T Orr, Christopher B Shields, Shirish S Barve, Kenneth G Pugh","doi":"10.1002/dad2.70438","DOIUrl":"https://doi.org/10.1002/dad2.70438","url":null,"abstract":"Introduction: The anti-amyloid monoclonal antibody donanemab (Kisunla™) treats patients with mild cognitive impairment or mild Alzheimer's disease.Methods: This study highlights 51 patients who received at least one donanemab infusion at our memory center between October 4, 2024 and October 3, 2025.Results: Of the 48 patients who underwent at least one surveillance brain MRI after starting donanemab, 10 (20.8%) had ARIA detected. ε4 carriers more frequently displayed amyloid-related imaging abnormalities (ARIA-cortical superficial hemosiderosis/microhemorrhages [ARIA-H] and/or ARIA-edema/effusion) (p = 0.033) and ARIA-H (p = 0.020) compared to ε4 non-carriers. No patients developed symptomatic ARIA. Seven (13.7%) patients experienced infusion-related side effects. Eight (15.7%) patients discontinued donanemab due to ARIA progression (5), severe infusion reactions (2), and need for anticoagulants (1).Discussion: Donanemab may be safely used in a real-world setting with structured monitoring. ARIA was observed in 20.8% of patients in this implementation cohort. Larger-scale multicenter data are needed to benchmark rates.","PeriodicalId":53226,"journal":{"name":"Alzheimer''s and Dementia: Diagnosis, Assessment and Disease Monitoring","volume":"18 3","pages":"e70438"},"PeriodicalIF":4.4,"publicationDate":"2026-08-18","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC13482909/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"148801525","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

Life's Essential 8™ and incident dementia in an urban cohort: Findings from the Northern Manhattan Study. 生活必需品™和城市队列中的痴呆事件：来自北曼哈顿研究的发现。

IF 4.4

Alzheimer''s and Dementia: Diagnosis, Assessment and Disease Monitoring Pub Date : 2026-08-18 eCollection Date: 2026-07-01 DOI: 10.1002/dad2.70444

Erin-Leigh Gallop, Pooja Kondeti, Hannah Gardener, Tatjana Rundek, Jose Gutierrez, Mitchell S V Elkind, Clinton B Wright, Bonnie Levin, Lily Wang, Christian Agudelo, Stephanie Assuras, Vanessa Guzman, Tali Elfassy

{"title":"Life's Essential 8™ and incident dementia in an urban cohort: Findings from the Northern Manhattan Study.","authors":"Erin-Leigh Gallop, Pooja Kondeti, Hannah Gardener, Tatjana Rundek, Jose Gutierrez, Mitchell S V Elkind, Clinton B Wright, Bonnie Levin, Lily Wang, Christian Agudelo, Stephanie Assuras, Vanessa Guzman, Tali Elfassy","doi":"10.1002/dad2.70444","DOIUrl":"10.1002/dad2.70444","url":null,"abstract":"Introduction: The American Heart Association's Life's Essential 8™ (LE8) defines cardiovascular health (CVH) using eight behavioral and clinical metrics. We examined the association between CVH and incident dementia.Methods: We used data from 920 dementia-free participants of the Northern Manhattan Study. LE8 scores (range: 0-100) were calculated from information on clinical and behavioral characteristics. Dementia was adjudicated by expert clinicians using neuropsychological assessments and clinical records. We used Cox proportional hazards models to determine associations adjusting for age, sex, race/ethnicity, education, and insurance.Results: Mean age was 64 years, 60% of participants were female, 65% were Hispanic, and mean LE8 score was 60. Over 9 years, 175 participants developed dementia. Each 10-unit decrement in LE8 score was associated with a greater risk of dementia (hazard ratio [HR]: 1.33; 95% confidence interval [CI]: 1.17-1.51).Discussion: CVH is important for brain health, and our results support interventions aimed at improving CVH for prevention of dementia.","PeriodicalId":53226,"journal":{"name":"Alzheimer''s and Dementia: Diagnosis, Assessment and Disease Monitoring","volume":"18 3","pages":"e70444"},"PeriodicalIF":4.4,"publicationDate":"2026-08-18","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC13482911/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"148801511","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

Regional amyloid accumulation, post-traumatic distress, and intrusive symptoms in cognitively unimpaired older adults at risk for Alzheimer's. 有阿尔茨海默氏症风险的认知未受损老年人的区域性淀粉样蛋白积累、创伤后应激和侵入性症状

IF 4.4

Alzheimer''s and Dementia: Diagnosis, Assessment and Disease Monitoring Pub Date : 2026-08-18 eCollection Date: 2026-07-01 DOI: 10.1002/dad2.70410

Eleni Palpatzis, Carmen M Colceriu, Mahnaz Shekari, Muge Akinci, Marc Suárez-Calvet, Oriol Grau-Rivera, Gonzalo Sánchez-Benavides, Juan Domingo Gispert, Eider M Arenaza-Urquijo

{"title":"Regional amyloid accumulation, post-traumatic distress, and intrusive symptoms in cognitively unimpaired older adults at risk for Alzheimer's.","authors":"Eleni Palpatzis, Carmen M Colceriu, Mahnaz Shekari, Muge Akinci, Marc Suárez-Calvet, Oriol Grau-Rivera, Gonzalo Sánchez-Benavides, Juan Domingo Gispert, Eider M Arenaza-Urquijo","doi":"10.1002/dad2.70410","DOIUrl":"https://doi.org/10.1002/dad2.70410","url":null,"abstract":"Introduction: In preclinical Alzheimer's disease (AD), early pathology may heighten vulnerability to psychiatric symptoms. We examined whether Aβ accumulation in cognitive-emotional regions was associated with post-pandemic psychiatric symptoms.Methods: This prospective cohort study included 115 cognitively unimpaired ALzheimer's and FAmilies participants (69 [60%] women, mean [SD] age 64.9 [4.8] years). Amyloid beta (Aβ) change was examined in anterior cingulate, posterior cingulate, superior parietal, medial orbitofrontal gyri, and insula using two [18F]flutemetamol positron emission tomography (PET) scans. Outcomes were pandemic-related post-traumatic distress (Impact of Events Scale Revised [IES-R]; total, intrusive, avoidance, and hyperarousal symptoms) and anxious-depressive symptoms (Hospital Anxiety and Depression Scale [HADS]; mean follow-up: 3.62 years [SD = 0.68]). Linear regression and voxel-wise analyses were performed.Results: Aβ accumulation across anterior cingulate (β = 40.29, p = 0.036), posterior cingulate (β = 29.52, p = 0.012), superior parietal (β = 35.58, p = 0.036), and medial orbitofrontal gyri (β = 35.08, p = 0.036) was associated with post-pandemic intrusive symptoms only, independent of baseline anxious-depressive symptoms.Discussion: Aβ accumulation in cognitive-emotional regions may increase vulnerability to intrusive symptoms, highlighting their potential as early clinical markers in AD.","PeriodicalId":53226,"journal":{"name":"Alzheimer''s and Dementia: Diagnosis, Assessment and Disease Monitoring","volume":"18 3","pages":"e70410"},"PeriodicalIF":4.4,"publicationDate":"2026-08-18","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC13482903/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"148801523","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

Clinical tools to differentiate behavioral variant frontotemporal dementia from phenocopies. 区分行为变异性额颞叶痴呆与表型的临床工具。

IF 4.4

Alzheimer''s and Dementia: Diagnosis, Assessment and Disease Monitoring Pub Date : 2026-08-17 eCollection Date: 2026-07-01 DOI: 10.1002/dad2.70452

Joshua Flavell, Soohyun Lee, Caitlin A T McElligott, Felicia M Coleman, Amir Fazlollahi, Emily G McCann, Duy D Nguyen, Peter J Nestor

{"title":"Clinical tools to differentiate behavioral variant frontotemporal dementia from phenocopies.","authors":"Joshua Flavell, Soohyun Lee, Caitlin A T McElligott, Felicia M Coleman, Amir Fazlollahi, Emily G McCann, Duy D Nguyen, Peter J Nestor","doi":"10.1002/dad2.70452","DOIUrl":"https://doi.org/10.1002/dad2.70452","url":null,"abstract":"Introduction: Behavioral variant frontotemporal dementia (bvFTD) is often misdiagnosed, particularly in psychiatric phenocopies of the disease (phFTD). We compared the top-performing bvFTD-specific behavioral tools, identified in a prior systematic review, for differentiating bvFTD from phFTD.Methods: In this prospective diagnostic accuracy study, consecutively recruited participants with suspected bvFTD by a specialist physician completed nine bvFTD-specific tools at baseline with a blinded assessor. Final diagnoses were assigned by multidisciplinary consensus after follow-up. Diagnostic performance was assessed using receiver operating characteristic analyses.Results: Fifty-one participants were included (25 bvFTD, 26 phFTD). The Frontotemporal Dementia versus Primary Psychiatric Disorder (FTDvsPPD) checklist showed the best discrimination (area under the curve [AUC] 0.92), with 80.0% sensitivity and 96.2% specificity. The Social Behavior Observer Checklist (SBOC) performed next best (AUC 0.85). The Informant Based Questionnaire and Pick's Disease Scale showed moderate discrimination and other tools performed poorly.Discussion: Tools focused on clinician observation outperformed informant-reliant measures. The FTDvsPPD checklist showed the strongest rule-in and rule-out utility, while the SBOC provided useful rule-in support.","PeriodicalId":53226,"journal":{"name":"Alzheimer''s and Dementia: Diagnosis, Assessment and Disease Monitoring","volume":"18 3","pages":"e70452"},"PeriodicalIF":4.4,"publicationDate":"2026-08-17","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC13482167/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"148801460","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0